

## HB 3192 STAFF MEASURE SUMMARY

### House Committee On Health Care

---

**Action Date:** 03/21/19

**Action:** Without recommendation as to passage, refer to Revenue by prior reference.

**Vote:** 10-0-1-0

**Yeas:** 10 - Alonso Leon, Boles, Drazan, Hayden, Keny-Guyer, Mitchell, Noble, Nosse, Prusak, Salinas

**Exc:** 1 - Greenlick

**Fiscal:** Fiscal impact issued

**Revenue:** Revenue impact issued

**Prepared By:** Oliver Droppers, LPRO Analyst

**Meeting Dates:** 3/21

---

#### **WHAT THE MEASURE DOES:**

Imposes annual assessment on manufacture of prescription opioids. Applies to opioids dispensed on or after January 1, 2020. Takes effect on 91st day following adjournment *sine die*.

#### **ISSUES DISCUSSED:**

- Measure not discussed; referral to another committee

#### **EFFECT OF AMENDMENT:**

No amendment.

#### **BACKGROUND:**

Addiction to and overdose from nonmedical use of prescription opioid pain medications in Oregon and across the nation has reached epidemic levels. In 2017, some estimates of collateral treatment costs rose to \$20 billion spent on emergency room visits and hospital care annually, not including impacts on the criminal justice system, systems that provide a spectrum of social services, and the costs of increasing litigation against the relevant drug manufacturers and doctors who prescribed them.

House Bill 3192 imposes an assessment of \$0.01 per morphine milligram equivalent per year on each manufacturer of prescription opioids dispensed in Oregon for use in the prevention, treatment, and safe recovery from opioid addiction and other substance use disorders.